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Structural variation of protein–ligand complexes
of the first bromodomain of BRD4†
Ellen E. Guest, a Stephen D. Pickettb and Jonathan D. Hirst *a
The bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extra-terminal
domain (BET) family, plays a key role in several diseases, especially cancers. With increased interest in
BRD4 as a therapeutic target, many X-ray crystal structures of the protein in complex with small molecule
inhibitors are publicly available over the recent decade. In this study, we use this structural information to
investigate the conformations of the first bromodomain (BD1) of BRD4. Structural alignment of 297
BRD4-BD1 complexes shows a high level of similarity between the structures of BRD4-BD1, regardless of
the bound ligand. We employ WONKA, a tool for detailed analyses of protein binding sites, to compare
the active site of over 100 of these crystal structures. The positions of key binding site residues show a
high level of conformational similarity, with the exception of Trp81. A focused analysis on the highly con-
served water network in the binding site of BRD4-BD1 is performed to identify the positions of these
water molecules across the crystal structures. The importance of the water network is illustrated using
molecular docking and absolute free energy perturbation simulations. 82% of the ligand poses were
better predicted when including water molecules as part of the receptor. Our analysis provides guidance
for the design of new BRD4-BD1 inhibitors and the selection of the best structure of BRD4-BD1 to use in
structure-based drug design, an important approach for faster and more cost-efficient lead discovery.
1 Introduction
The bromodomains and extra-terminal domain (BET) family of
proteins recognize acetylated N-terminal tails of histones
through interactions of their bromodomains (BDs) and acetyl-
ated lysine residues.1,2 BET proteins play a crucial role in regu-
lating gene expression and are an important target to develop
inhibitors to regulate protein expression by inhibiting these
epigenetic interactions. The most extensively studied member
of the BET family is the bromodomain-containing protein 4
(BRD4), because of its promise as a therapeutic target for dis-
eases such as cancer, neurodegenerative disorders, inflam-
mation and obesity.3–7 Increased interest in BRD4 and its
potential inhibitors has resulted in a wealth of X-ray crystal
structures, providing atomistic insight into its binding site
interactions. However, this also means that it is increasingly
difficult to choose which crystal structure is preferred as the
starting point of any in silico study. Within this work, we use
the structural information, which is publicly available, to help
understand the flexibility of BRD4 and examine the effects of
small molecule inhibitors, with a focus on the BD1 binding
pocket. This analysis provides guidance in selecting crystal
structures and other features, such as crystallographic water
molecules.
Like its family members, BRD2, BRD3 and BRDT, BRD4
consists of two N-terminal BDs (BD1 and BD2) and an extra
C-terminal domain (ET).8 Each BD is composed of four helices
(αZ, αA, αB and αC), which are connected by the ZA loop and
BC loop, creating the acetyl-lysine binding site (Fig. 1a). BRD4-
BD1 recognises histone H4, which is anchored by a hydrogen
bonding interaction between the carbonyl oxygen atom on the
acetylated lysine and an asparagine residue Asn140 on the BC
loop of the receptor (Fig. 1b).9 A second interaction is formed
through a water mediated hydrogen bond between the acetyl
lysine and tyrosine residue Tyr97 on the ZA loop. Additional
binding site residues create a deep hydrophobic cavity, with
Trp81 and Met149 also considered key residues in H4 and
small molecule inhibitor binding.10 Over the last decade, there
have been many small molecule inhibitors published, with
some of them reaching human clinical trials.11–16 Contained
within these inhibitors is a wide chemical diversity with core
motifs encompassing azepines, 3,5-dimethyl isoxazoles, pyri-
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dones, triazolopyridines, tetrahydroquinolines, 4-acyl pyrroles
and 2-thiazolidinones.17,18 Each of these structural classes
contains a unique warhead, which competes with H4 to repli-
cate the interactions with Asn140 and Tyr97. An additional
common feature of small drug-like compounds bound to
BRD4-BD1 is a lipophilic group, which can extend into the
binding pocket and interact with the hydrophobic WPF shelf
(Trp81-Pro82-Phe83).
The consideration of water molecules is important for
ligand binding, as they can stabilize a complex by acting as a
bridge for hydrogen bonds and their displacement by a ligand
can result in a decrease in binding affinity of that ligand.19
However, it is also possible for displacement to be associated
with a favorable gain in entropy with the release of a well-
ordered molecule into the bulk solvent, resulting in an
increase in ligand binding affinity. It is therefore crucial in
drug design to understand which water molecules mediate
protein–ligand interactions and which can be targeted for dis-
placement. At the base of the BRD4-BD1 binding pocket, there
is a network of highly conserved water molecules, which has
been found to be important in ligand binding and stabilising
the protein structure.10,20,21 Zhong et al.22 investigated the
structural and thermodynamic properties of the crystallo-
graphic water molecules. They found that it is energetically
unfavourable to displace a water molecule with a small drug-
like compound, as this would require a large amount of energy
to compensate breaking the hydrogen bonding network.
Furthermore, molecular dynamics simulations demonstrated a
high occupancy for several of the water sites. Using these find-
ings, Zhong et al. developed a docking based virtual screening
protocol to identify novel inhibitors towards BRD4. This study
highlighted the importance of the water network in structure-
based drug design.
The pool of BRD4 inhibitors continues to grow, with most
identified through fragment or structure-based drug design
based on properties of known BRD4 inhibitors.23–27
Additionally, a recent review28 identified three novel strategies
in targeting BRD4, including bivalent BRD4 inhibitors, proteo-
lytic targeting chimeric molecules and re-purposing of kinase
inhibitors. The selectivity of inhibitors is also being
targeted.29–31 Initially many compounds were developed as
BRD4 inhibitors. However, due to the structural similarity
across the BDs of BET proteins, many of these were pan-inhibi-
tors which could cause adverse side effects such as dizziness
and nausea.32,33 Gilan et al.29 used structure-based design to
discover compounds that interact specifically with either the
BD1 or BD2 of BET proteins, providing new insights into
improving therapeutic strategies with fewer toxic side effect.
Speck-Planche et al.31 have also developed the first multi-
target quantitative structure activity relationship (mt-QSAR)
model, which can predict BET inhibitor potency against BRD2,
BRD3 and BRD4.
As in many drug discovery campaigns, computational
methods remain an important tool in finding BRD4
inhibitors.23,25,34,35 Structure based virtual screening methods,
such as docking and 3D-QSAR, can facilitate high-throughput
approximations of binding affinities. Molecular dynamics
simulations expand on static representations of protein–ligand
Fig. 1 (a) Structure of BRD4-B1 (PDB 3UVW) with histone H4 (light blue) bound. (b) Binding site of BRD4-BD1. Key binding site residues are high-
lighted as sticks. Histone H4 is shown in light blue, with acetylated lysine residues shown as sticks. Water molecules at the base of the binding site
are shown as red spheres. (c) The common sequence of BRD4-BD1 across the X-ray crystal structures in our data set. Secondary structures of
α-helices αZ, αA, αB and αC are coloured in red, blue, green and orange, respectively.
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complexes by providing a more dynamic view and develop our
understanding of structural patterns and interactions, which
lead to high potency and selectivity.36,37 As a crucial goal of
drug development is designing a compound that binds compe-
titively and strongly, alchemical free energy calculations are
becoming increasingly important as, when done well, they can
provide accurate estimations of binding free energies and
present a way to minimize the number of compounds that are
made in the laboratory. Pan et al.23 discovered a BRD4-histone
deactylase (HDAC) inhibitor, a promising therapeutic strategy
for colorectal carcinoma, through high-throughput rigid mole-
cular docking of fragments of known BRD4 inhibitors,
embedded into the fragment-like library of ZINC.38 A flexible
docking method was then implemented on the top 200
scoring fragments. Following this docking, 24 compounds
were synthesised and tested based on the 10 top scoring frag-
ments, resulting in a promising lead compound. The extensive
research already conducted on BRD4 and its inhibitors also
makes it an excellent test case for the development of novel
computational workflows. For example, Fusani et al.39 merged
active learning with the comparative binding energy
(COMBINE) method and demonstrated its performance using
a BRD4 dataset. Active learning was used to introduce an
uncertainty estimation component to the COMBINE method,
which is a powerful tool in studying the structural information
of protein–ligand complexes and deriving QSAR for structu-
rally similar series of compounds.
A fundamental component of structure based in silico
methods is the use of X-ray crystal structures. It is therefore
important to be able to rely on the starting conformations of
proteins in order to make accurate predictions. For example,
different active site conformations may lead to different
binding poses, which can severely impact predicted binding
affinities.40,41 While molecular dynamics simulations, com-
bined with enhanced sampling methods, can be used to find
the most stable binding pose, these methods come with a com-
putational expense and it is still sensible to choose the starting
structure with care. In a study on the T4 lysozyme L99A, Lim
et al.42 demonstrated that predicted relative free energy values
are sensitive to initial protein conformation, even when using
enhanced sampling. In our study, we examine the X-ray crystal
structures of BRD4-BD1 complexes in the PDB and perform
structural clustering, to identify the variation of conformations
and the best static representative structures of the receptor. To
compare the binding site of multiple complexes and identify
ligands which cause structural variation, we use WONKA.43,44
WONKA is a tool for ligand-based, residue-based and water-
based analyses of protein–ligand structural ensembles. The
advantage of using WONKA over other visualisation and ana-
lysis tools, such as PyMOL,45 is its ability to identify trends
within a data set. It can identify patterns between structure
and individual ligand complexes, and these observations are
displayed on a web based graphical user interface. WONKA
also analyses water displacements and relates which ligands
displace conserved water molecules. Therefore, we are able to
explore the extent of the conservation of crystallographic water
molecules in the BRD4-BD1 binding pocket and highlight
functional groups present in the ligands, which displace the
usually highly conserved water network. Molecular docking is
also used to assess the accuracy of predicted binding poses,
with and without the water network present.
2 Materials and methods
Structural data
A survey of the PDB reveals, at the time of this study, 323 X-ray
crystal structures of BRD4 in complex with a variety of ligands.
To identify the common sequence, multiple sequence align-
ment was performed using the Clustal Omega46 alignment
tool in Chimera.47 Sequence alignment shows that 26 of the
ligands are co-crystallised with BD2 and are therefore dis-
counted. In total, 297 BRD4-BD1 complexes are taken forward
for further analysis.
Structural clustering
To prepare the receptor structures for clustering, the ligands
were first removed, multiple sequence alignment was per-
formed and the common sequence across all structures
(Fig. 1c) was retained, with the remaining tails removed.
Protein structural clustering was performed using ClusCo,48 a
software tool for the clustering and comparison of protein
models. This utilizes an open source K-means49 code for
Hierarchical Agglomerative Clustering. To identify a sensible
number of groups to cluster the structures into, all-vs-all pair-
wise root-mean-square deviation (RMSD) values were calcu-
lated. RMSD was based on Cα atoms. The centroid of the
whole ensemble was established by clustering with the cluster
number set to one.
Although there is no specified upper limit to the number of
crystal structures that WONKA can analyse, we found that a
cutoff of 100 structures is preferable for the software to
perform smoothly. To ensure that effects of a wide range of
ligand activity and structural diversity were captured, the
crystal structures studied using WONKA were chosen based on
structural clustering of the co-crystallised compounds. Out of
the 297 crystal structures of BRD4-BD1, there are 266 unique
ligands in complex with the receptor, which have accessible
experimental data. Compounds that show little or no activity
(pIC50 < 5) were discounted, leaving 175 compounds to be
clustered. Ligand structural clustering was performed in
DataWarrior,50 using Fragp descriptors and Tanimoto simi-
larity (T ). Two structures were considered to be similar if T >
0.8. Representative compounds from each cluster, and their
respective crystal structures, were chosen for analysis using
WONKA.
Molecular docking
The representative compounds from ligand-based clustering
were selected for molecular docking. Ligand coordinates were
extracted from their original crystal structures and docked
against the centroid crystal structure of BRD4-BD1 (PDB 4BJX),
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with and without the water network included as part of the
receptor. All other crystallographic water molecules were
removed in both cases. To prepare the crystal structure for
docking, the receptor generation software as part of the
OpenEye docking toolkit51,52 was used. The co-crystallised
compound with ID 73B was assigned as the ligand and there-
fore did not interact with docked molecules. A box centred
around the original ligand with sides of length 15.7 Å × 20.7 Å
× 19.0 Å was situated to cover the BRD4-BD1 binding cavity,
giving a total receptor volume of 6151 Å3. Constraints were
applied to ensure a heavy atom contact with Asn140.
Compounds to be docked were protonated according to physio-
logical pH and prepared using OpenEye OMEGA.52
Conformers were generated using a truncated form of the
MMFF94s force field53 with a maximum energy difference of
20 kcal mol−1 set from the lowest energy conformer. A
maximum of 1000 conformers was allowed and those within
0.5 Å of any others were considered as duplicates and removed.
Docking was performed using OpenEye FRED.51 Compounds
were docked using the high resolution setting with rotational
and translational step sizes of 1 Å. To measure the accuracy of
the docking with and without the water network present, heavy
atom RMSD was calculated between the docked poses and the
crystallographic poses of each of the ligands.
Absolute free energy calculations
Absolute free energy perturbation (FEP) simulations were per-
formed to calculate binding free energies. To illustrate the
impact of starting structure, two calculations were performed,
each starting from a different binding pose of the same ligand.
Initial coordinates were obtained from the molecular docking
study, where the ligand (PDB 83T) was docked to the centroid
structure of BRD4-BD1 (PDB 4BJX), with and without active
site crystallographic water molecules. This binding site water
network was retained for the FEP calculation in the case where
it had been involved in the docking. System preparation and
the simulations were performed using GROMACS 2020.3 54
and the CHARMM force field.55 Ligand parameters were gener-
ated using CGenFF.56 The complexes were solvated in a dode-
cahedral box with an edge distance of 3 nm, to construct an
explicitly modelled solvent consisting of around 32 000 TIP3P
water molecules57 and two Cl− ions to give a net neutral
charge. In absolute FEP simulations, ligand binding affinity is
estimated by calculating the difference between the free energy
change of decoupling the ligand from solution and decoupling
from the receptor. Therefore, a system was also prepared with
the ligand free in solution. Upon setup, systems were mini-
mized for 200 ps using a steepest descent algorithm.
Equilibration was performed for 200 ps in the NVT ensemble
with harmonic position restraints applied to the heavy atoms
with a force constant of 1000 kJ mol−1 nm−2. Temperature
coupling was achieved by using velocity rescaling with a sto-
chastic term and a reference temperature of 298 K. A further
equilibration was performed for 4 ns in the NPT ensemble
with a Berendsen pressure and temperature coupling scheme.
The decoupling of the ligands from the receptor was split into
30 lambda windows, where ligand restraints were applied and
van der Waals and Coulomb interactions were gradually
turned off. The relative positions of the ligands with respect to
the receptor were restrained by one bond, two angles and three
dihedral harmonic potentials. To account for these restraints,
a correction is applied to the free energy of binding. For the
free ligand in solvent, van der Waals and Coulomb interactions
were decoupled over 20 lambda windows. Each lambda
window consisted of 1 ns of equilibration in the NPT ensem-
ble, followed by 2 ns of data collection. Free energy changes
were evaluated with the Bennett Acceptance Ratio (BAR)
method58 as implemented in GROMACS.
3. Results and discussion
Receptor based structural clustering
Fig. 2 shows the distribution of the resolution of the crystal
structures identified in the PDB; they have an average resolu-
tion of 1.60 Å. Overall, we can consider the structures to be
high-resolution and have confidence in the quality of the
crystal structure data.
Structural differences within the ensemble of crystal struc-
tures were measured using pairwise RMSD. The median and
mean pairwise RMSDs are 0.56 Å and 0.58 ± 0.22 Å respect-
ively. These RMSD values are small and suggest high similarity
between most protein structures within the ensemble. The
structural similarity between the superimposed structures can
be observed in Fig. 3a. The maximum pairwise RMSD is 1.70 Å
between PDB entries 5KU3 and 6V1L. The overlay of these
structures (Fig. 3b) suggests the largest structural variance
occurs in the tail leading to the N-terminus. There is a small
amount of deviation in the ZA loop. Given the narrow distri-
bution of RMSD values, it is sensible to group the structures
into five clusters. Fig. 4 shows an overlay of the representation
crystal structures of the five structural clusters. The position of
Fig. 2 Distribution of the resolution of 297 X-ray crystal structures of
BRD4-BD1 complexes (dark grey) and the 101 crystal structures analysed
using WONKA (light grey).
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the binding site residues further demonstrates the similarity
between different structures of the receptor. The centroid of
the whole ensemble is the crystal structure with PDB code
4BJX, which has a resolution of 1.59 Å. With such a high
number of crystal structures available for BRD4, these results
can aid the selection of the most representative structures to
use for the computational study of BRD4-BD1.
Ligand based structural clustering
Clustering the co-crystallised ligands, which have experimental
pIC50 values of >5, based on structural similarity resulted in
101 groups. The distribution of ligand activity for the whole
data set and the 101 representative compounds from each
cluster is shown in Fig. 5. The representative compounds have
a pIC50 range of 5.0 to 8.8 and cover a relatively wide span of
activity. Therefore, no further filtering of the compounds was
performed and the complexes containing these ligands were
taken forward for analysis using WONKA.
Structural diversity of the binding site
WONKA enables the identification of trends in the position of
active site residues for multiple crystal structures of the same
protein. Fig. 6 shows the superimposition of the key binding
site residues in BRD4-BD1 for each of the co-crystal structures,
identified by ligand based structural clustering. WONKA clus-
ters a particular residue’s conformations into different groups
based on an all-vs-all heavy atom RMSD of 2.5 Å between like-
residues in a structural ensemble. Asn140, Tyr97, Met149,
Trp81, Pro82 and Phe83 show 5, 3, 6, 9, 4 and 2 clusters
respectively.
Visual inspection reveals that all key binding site residues,
with the exception of Trp81, have a high level of conformation-
al similarity across all of the crystal structures, regardless of
the structure or activity of the bound ligand. There are three
structures of Trp81 that show dissimilar conformations, high-
lighted in blue, red and green in Fig. 6. There are multiple
factors that could play a role in the observed disorder of Trp81.
It is important to recognise that these crystal structures
provide information on only one static conformation. A
Fig. 3 (a) Superimposed structures of 297 BRD4-BD1 X-ray crystal
structures available in the PDB. (b) Comparison of structures PDB 5KU3
(blue) and 6V1L (orange), which have the highest pairwise RMSD.
Fig. 4 Representative X-ray crystal structures after grouping 297 crystal
structures of BRD4-BD1 into five clusters. The PDB codes for the struc-
tures are 5WA5 (purple), 4PS5 (red), 5NNE (blue), 5D0C (yellow), 5U28
(lime) and 4BJX (orange). (a) Secondary structures of the five representa-
tive structures. (b) Active site of the five structures, key binding residues
are highlighted as sticks. (c) The resolutions of each X-ray crystal
structure.
Fig. 5 Distribution of pIC50 values for the representative 101 com-
pounds (shaded) compared to the total data set (open).
Fig. 6 The position of key binding site residues in BRD4-BD1 over 101
X-ray crystal structures. Conformations of Trp81, which show the largest
deviation, are shown in blue, red and green.
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protein is flexible in solution, and it is possible that the posi-
tions of these Trp81 residues are more ordered when sampling
a different conformation. Interactions with other amino acids
within the protein and with the bound ligand can also influ-
ence the position of binding site residues. The bound ligands
that correlate with these deviations in Trp81 position are
shown in Fig. 7. The compounds have experimental pIC50
values of 5.26, 5.89 and 5.20, which are towards the lower end
of the range. As these values were measured using different
biological assays, we should be cautious about directly com-
paring them with each other and the remaining dataset.59
However, for a potent compound, we would expect a pIC50
value upwards of 7.5, regardless of the assay conditions. A
possible reason for these Trp81 positions could be that any
hydrophobic interactions formed by the ligand with Trp81 do
not outweigh the stability gained by polar ligand atoms
forming solvent interactions. No additional binding site
residue interactions are observed, in place of an interaction
with Trp81. Therefore, compounds that result in this disorder
of Trp81 are not desirable and do not correlate with higher
binding affinity. Furthermore, it would be sensible to use
structures with a ‘regular’ Trp81 position for the basis of com-
putational studies.
Active site water molecules
It is well documented that a network of conserved water mole-
cules plays an important role in BRD4-BD1 ligand
binding.20–22,29,60,61 Including crystallographic water molecules
is an important consideration for computational studies, and
there has been many tools developed to locate water molecules
in protein binding sites.62–65 Crystallographic water molecules
can drastically change the binding mode in protein–ligand
docking22 and also provide stability to the system in more
advanced methods such as binding free energy calculations.66
As part of our exploration of X-ray crystal structures, we used
WONKA to analyse the occupancy of the water network, which
lines the BRD4-BD1 binding pocket, as shown in Fig. 8. From
the positions of the water molecules, we can identify that the
water molecule at site 2 mediates a hydrogen bond between
Tyr97 and bound ligands. The size of the red spheres, which
represent crystallographic water molecules, reflect how con-
served they are across the ensemble of crystal structures. For
example, the sphere at site 1 is the largest as there is only one
crystal structure, which does not include a water molecule at
this position. All water clusters within 8 Å of the ligand are dis-
played and there is a maximum distance of 1.5 Å between a
point in a cluster and the cluster centre.
Using WONKA, we can easily identify the ligands which dis-
place the water molecules in the sites where they are not
present. The only crystal structure with no water molecules at
site 1 or 2 is PDB 6MH1 (Fig. 9). Water molecules at sites 3
and 4 are also displaced. Divakaran et al.67 acknowledge the
reorganisation of the usually conserved water network and
attribute it to the fluorophenyl group of the ligand. A moderate
pIC50 value of 5.77 was measured for this compound.
However, increased selectivity over other BET receptors was
observed and it was hypothesised that this was in part due to
the displacement of the water molecules. In our ensemble of
crystal structures, which were analysed using WONKA, there
are no other fluorine containing groups which occupy the
Fig. 7 The three crystal structures and corresponding ligands, which contain Trp81 conformations most dissimilar from the whole PDB ensemble.
Fig. 8 Crystallographic water molecules (red) in the binding pocket of
BRD4-BD1 (orange). The size of the spheres indicate the extent of their
conservation across 101 crystal structures. For perspective, a small
molecule binder (PDB 3ZYU) is shown in blue.
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same region of the binding site, which perhaps explains why
sites 1, 2, 3 and 4 are occupied by water molecules for the
majority of remaining complexes.
Beside the structure previously discussed, there is one
other crystal structure, PDB 5I88, which does not show water
molecules at sites 3 and 4. The butenyl group on the ligand
displaces the water network and induces a rearrangement. The
addition of a butenyl group to the compound corresponds
with a reduction in activity as the butenyl containing com-
pound has a pIC50 of 6.43, while its equivalent without the
butenyl group has a pIC50 of 7.04. Crawford et al.
21 suggest
that, while there may be multiple parameters that contribute
to the decreased potency, the position of the active site water
molecules may play a role.
Site 5 is occupied by a water molecule in all crystal struc-
tures, with the exception of PDB 4GPJ and 5DLZ. The displace-
ment of this water molecule does not correlate with high
activity ligands. Furthermore, there are ten crystal structures in
our data set, which do not contain a water molecule at site 6.
The corresponding ligands for these crystal structures have a
pIC50 range of 5.30 to 7.30. The remaining water molecules
depicted in Fig. 8 are present in ≤80% of the crystal structures
(see ESI† for a full list of PDB codes and the presence of active
site crystallographic water molecules in each). While we have
not found a correlation between the displacement of specific
water molecules in the network and the activity of the co-crys-
tallised compounds, we have demonstrated the extent of their
conservation. We expect this analysis to be a useful tool in
selecting the best crystal structure and number of crystallo-
graphic water molecules to retain in computational studies of
BRD4-BD1.
Molecular docking
To demonstrate the importance of the conserved binding site
water network in modelling an experimentally accurate system,
molecular docking was performed with and without the pres-
ence of the water network. Ligands from 101 crystal structures
of BRD4-BD1 complexes were docked against structure PDB
4BJX. To compare the two setups, the RMSD values between
the docked poses and the crystallographic poses were calcu-
lated. On average, the improvement in RMSD when including
the water molecules was 1.52 Å (distributions of each data set
can be found in the ESI†). Furthermore, 82% of the ligand
poses were better predicted when including water molecules
as part of the receptor. For example, Fig. 10 shows a large
difference in bound conformation of one of the compounds.
The docked pose has a RMSD of 0.21 Å when water molecules
are included and 1.54 Å when docked without water molecules.
Different functional groups occupying different regions of the
active site, such as in this example, can lead to large differ-
ences in predicted activity when using more involved, but
more accurate, methods such as free energy calculations. The
accuracy of the binding poses when docking with the con-
served water molecules indicates that these water molecules
should be retained in computational studies of BRD4-BD1.
Furthermore, this aids the design of new inhibitors.
Compounds should be designed with these solvent inter-
actions in mind, while all other crystallographic water mole-
cules are likely to be able to be displaced.
The receptor used in this study was the centroid of the
ensemble of 297 PDB crystal structures of BRD4-BD1.
Regardless of the inclusion of crystallographic water molecules
as part of the receptor, all docked compounds show a good
similarity to their original crystallographic conformations.
This indicates that crystal structure 4BJX is a suitable starting
conformation for the in silico study of BRD4-BD1.
Binding free energies
To further illustrate the impact of binding site water mole-
cules, the free energy of binding was calculated for the two
docked poses shown in Fig. 10. The orange structure is the co-
crystallised binding conformation of the compound. The struc-
ture in light blue is the docked pose when including the active
site water network and the green pose is the docked pose
obtained without including the water molecules. The experi-
mental binding free energy for the compound is −8.9 kcal
Fig. 9 The structure of the compound that displaces crystallographic
water molecules at sites 1–4 is shown on the left. The structure on the
right displaces water molecules at sites 3 and 4.
Fig. 10 Docked poses with (light blue) and without (green) including
crystallographic water molecules as part of the receptor. The crystallo-
graphic pose (orange) is also shown for comparison.
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mol−1.68 Absolute FEP resulted in a predicted binding free
energy of −11.2 ± 0.6 kcal mol−1 for the light blue binding
pose and a value of −1.5 ± 0.5 kcal mol−1 for the green pose.
There are a number of factors that can affect the accuracy of
FEP calculations, such as the quality of the small molecule
force field parameters and the number of lambda windows
used. However, the only difference in procedure between our
two calculations was the inclusion of the active site water mole-
cules in the generation and setup of the simulation starting
conformations. The large difference between our predicted
free energy values demonstrates the importance of starting
structure in these types of calculations. Furthermore, the
inclusion of water molecules resulted in a free energy of
binding which is closer to experiment. This supports our con-
clusion that these water molecules are crucial for accurately
modelling a BRD4 system.
4 Conclusions
There has been increasing interest in BRD4 as a therapeutic
target, resulting in a large number of X-ray crystal structures of
the receptor in complex with small molecule ligands. In this
work, we review an ensemble of structures of BRD4-BD1 com-
plexes in order to compare different conformations of the
protein, without the need, for example, to carry out molecular
dynamics simulations. By superimposing 297 crystal structures
of BRD4-BD1 and calculating pairwise RMSD values, we have
found a high level of similarity between the conformations,
regardless of the bound ligand. Clustering algorithms identify
PDB 4BJX as the centroid of the ensemble and clustering into
five groups gave structures 5WA5, 4PS5, 5NNE, 5D0C and 5U28
as the representative structures of each cluster.
To achieve a more detailed view of the binding site, we used
WONKA to compare the conformations of individual residues
that are important for histone and small molecule binding. In
this analysis the positions of Asn140, Tyr97, Met149, Trp81,
Pro82 and Phe83 in 101 X-ray crystal structures were compared.
With the exception of a handful of Trp81 conformations, the
positions of these residues were extremely similar. This shows
the size and shape of the BD1 cavity remains unchanged with
different ligands bound, highlighting the importance of the
chemical features needed in a potential inhibitor. A polar
group at the head of the ligand is necessary to form both the
interaction with Asn140 and a water mediated interaction with
Tyr97. Simultaneously, a lipophilic group is needed to extend
into the hydrophobic cavity of BD1 and strengthen ligand
binding.
Water molecules also play an important role in BRD4
ligand binding. Therefore, we examined the conservation of
crystallographic water molecules in the binding site. Analysis
in WONKA showed that the majority of crystal structures
contain the four or five water molecules generally considered
important for ligand binding. In total, there are up to 11 water
molecules within 8 Å of the bound ligands, which are largely
conserved across the ensemble. While there have been pre-
vious studies on this highly conserved water network,21,22 ours
is the first to consider such a high number of experimental
structures. Our work demonstrates the extent of the conserva-
tion and, through molecular docking and absolute FEP calcu-
lations, highlights the importance of retaining binding site
water molecules in computational studies. Through this exam-
ination of BRD4-BD1 crystal structures, we have provided a
quantitative basis to facilitate the selection of structures in
future computational studies.
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